$9.46
-2.2%eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
EXOZ • NASDAQ
| eXoZymes, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
3M | 9.7M | 66.5K | 558.6K | 547.8K | |
3M | 9.7M | 66.5K | 558.6K | 547.8K | |
517.4K | 737.3K | 882.3K | 809.5K | 468.4K | |
517.4K | 737.3K | 882.3K | 809.5K | 468.4K | |
382.9K | 363.8K | 264.8K | 101.1K | 30.2K | |
3.9M | 10.8M | 1.2M | 1.5M | 1M | |
NON-CURRENT ASSETS | |||||
2.2M | 2.2M | 2.3M | 1.2M | 1.3M | |
-176.8K | 0.0 | 0.0 | 0.0 | 0.0 | |
2M | 2.2M | 2.3M | 1.2M | 1.3M | |
6M | 13M | 3.6M | 2.7M | 2.3M | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
1.2M | 1.1M | 1.2M | 489.4K | 267.3K | |
1.2M | 924.3K | 702.9K | 385.8K | 267.3K | |
5.3K | 179K | 487.4K | 103.6K | 0.0 | |
326.2K | 230K | 225K | 145K | 133.5K | |
0.0 | 0.0 | 42.3K | 63.6K | 0.0 | |
0.0 | 0.0 | 1M | 0.0 | 0.0 | |
1.6M | 1.3M | 2.4M | 634.4K | 400.8K | |
NON-CURRENT LIABILITIES | |||||
0.0 | 0.0 | 140.7K | 215K | 161.1K | |
90.4K | 123.6K | 0.0 | 0.0 | 0.0 | |
1M | 1.3M | 1.5M | 678.8K | 748.2K | |
1.2M | 1.4M | 1.6M | 608.8K | 720.6K | |
2.6M | 2.6M | 3.9M | 1.3M | 1.1M | |
SHAREHOLDERS' EQUITY | |||||
8.0 | 8.0 | 6.0 | 6.0 | 12.0 | |
24.5M | 22.4M | 5.7M | 5.4M | 3.8M | |
-21.1M | -11.9M | -6.1M | -4M | -2.7M | |
3.4M | 10.4M | -384.3K | 1.4M | 1.2M | |
3.4M | 10.4M | -384.3K | 1.4M | 1.2M | |
SUMMARY | |||||
6M | 13M | 3.6M | 2.7M | 2.3M | |
1.2M | 1.4M | 1.6M | 608.8K | 720.6K | |
-1.8M | -8.3M | 1.5M | 50.2K | 172.8K | |
8,387,250 | 8,387,250 | 8,387,250 | 8,387,250 | 8,387,250 |
EXOZ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | January 29, 2026 | 2026 | |
S-3 S-3 N/A | January 16, 2026 | January 16, 2026 | ||
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your EXOZ research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.